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Many patients suffering from developmental disorders harbor submicroscopic deletions or duplications that, by affecting the copy
number of dosage-sensitive genes or disrupting normal gene expression, lead to disease. However, many aberrations are novel or
extremely rare, making clinical interpretation problematic and genotype-phenotype correlations uncertain. Identiﬁcation of patients
sharing a genomic rearrangement and having phenotypic features in common leads to greater certainty in the pathogenic nature of
the rearrangement and enables new syndromes to be deﬁned. To facilitate the analysis of these rare events, we have developed an inter-
active web-based database called DECIPHER (Database ofChromosomal Imbalance and Phenotype inHumans Using Ensembl Resources)
which incorporates a suite of tools designed to aid the interpretation of submicroscopic chromosomal imbalance, inversions, and trans-
locations. DECIPHER catalogs common copy-number changes in normal populations and thus, by exclusion, enables changes that are
novel and potentially pathogenic to be identiﬁed. DECIPHER enhances genetic counseling by retrieving relevant information from
a variety of bioinformatics resources. Known and predicted genes within an aberration are listed in the DECIPHER patient report,
and genes of recognized clinical importance are highlighted and prioritized. DECIPHER enables clinical scientists worldwide tomaintain
records of phenotype and chromosome rearrangement for their patients and, with informed consent, share this information with the
wider clinical research community through display in the genome browser Ensembl. By sharing cases worldwide, clusters of rare cases
having phenotype and structural rearrangement in common can be identiﬁed, leading to the delineation of new syndromes and
furthering understanding of gene function.Advances in molecular cytogenetic techniques and
sequencing of the human genome now enable chromo-
some rearrangements to be analyzed at an unprecedented
level of accuracy. The resolution of conventional Giemsa-
banded chromosome analysis is approximately 5–10 Mb,
whereas that of a typical high-density genomic array is
approximately 100 kb or less, resulting in an at least
50-fold improvement in sensitivity. With high-resolution
genomic-array analysis, disorders of chromosome imbal-
ance (copy number change) can now be identiﬁed with
such precision that mapping the rearrangements onto
the reference sequence of the human genome becomes
a realistic proposition.
Array comparative genomic hybridization (array-CGH)
and genomic copy-number analysis with SNP genotyping
arrays are proving particularly effective for the investiga-
tion of patients with developmental delay, learning
disability, dysmorphic features, and/or congenital anoma-
lies and are identifying the probable underlying cause of
the disease phenotype in approximately 15% of previously
undiagnosed cases.1–5 Moreover, a genomic basis to several
later-onset disorders, e.g., early-onset Alzheimer disease
with amyloid angiopathy (EOAD)6 and adult-onset auto-
somal-dominant leukodystrophy7, has now been deﬁned.
However, copy-number changes in many patients are
novel or extremely rare, such that uncertainty remains as
to whether the aberration is pathogenic or simply a benign
variant. Identiﬁcation of additional patients who share
a region of genomic deletion or duplication and have524 The American Journal of Human Genetics 84, 524–533, April 10phenotypic features in common allows greater certainty
to be given to the pathogenic nature of the rearrangement
and delineation of new syndromes.
Several studies have highlighted the presence of large
numbers of deletions, insertions, and duplications, ranging
from a few kilobases to several megabases in size, in the
normal population.8,9 For example, using the complemen-
tary technologies of single-nucleotide polymorphism (SNP)
genotyping arrays and clone-based comparative genomic
hybridization, Redon et al10 generated a global map of
copy-number variable regions (CNVRs) in the human
genome and found 1447 CNVRs covering approximately
12% of the human genome. As more studies are completed
and as the resolution of genomic array analysis increases,
more CNVRs are being discovered. There are currently
more than 6000 copy-number-variant loci listed in the
Database of Genomic Variants (DGV). These regions
contain several hundreds of genes, disease loci, and
segmental duplication regions. Because patients also have
these normal copy-number variants it has become a chal-
lenge to identify which changes are normal variants and
which are likely to be associated with a phenotype.
Although many clinical centers are now applying
genomic microarray technology to investigate patients
with developmental delay, learning disability, and congen-
ital malformation,11 the sporadic nature and rarity of the
majority of these cases limits the ability of the individual
clinician to interpret the molecular ﬁndings from
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Figure 1. Overview of DECIPHER
The DECIPHER database is accessed via the World Wide Web so that patient phenotypic and genomic information can be deposited in
a secure and private project areas by consortium members. Interaction with bioinformatic tools allows clinicians and scientists to inter-
pret the genomic information. With informed consent, data become viewable within the Ensembl genome browser so that patients with
overlapping copy-number changes can be readily identified.for international collaboration in the reporting and cata-
loguing of genotype-phenotype correlations such that
clusters of individuals sharing similar genomic rearrange-
ments and phenotypes can be identiﬁed. This will not
only facilitate diagnosis and genetic counseling but also
improve our understanding of gene function and disease.
The DECIPHER database (Database of Chromosomal
Imbalance and Phenotype in Humans Using Ensembl
Resources) and project (Figure 1) was initiated in 2004
with the general aim of providing a clinical and research
tool to (1) aid in the interpretation of data from genomic
microarray analysis, e.g., the differentiation between path-
ogenic and polymorphic copy-number changes; (2) utilise
the human genome map via the Ensembl genome browser
to deﬁne genes involved in a speciﬁcmicrodeletion, micro-
duplication, translocation, or inversion; and (3) facilitate
collaboration between clinical geneticists and molecular
cytogeneticists to accelerate progress in the delineation
of new syndromes and of gene function.
The acronym DECIPHER was chosen for the database
because the word means ‘‘To give the key to, to discoverThe Amthe meaning of [something obscure and perplexing].’’12
DECIPHER was granted Multi-Centre Research Ethics
Committee (MREC) approval (04/MRE05/50) in the UK.
The project has been made possible by several indepen-
dent but interlinked developments, including the Human
Genome Mapping Project, bioinformatic integration of
genomic information in genome browsers, and advances
in molecular cytogenetics. The Human Genome Mapping
Project provided a ﬁnished human genome sequence in
October 200413,14, and this acts as a reference sequence,
or assembly map, onto which chromosome rearrange-
ments and the order and position of genes and predicted
genes can be placed. Crucial to the operation of DECIPHER
was the development of the Ensembl genome browser15
which allows users to select and view an annotated
segment of the human genome map and connect to other
relevant resources via hyperlinks. The clone resources
developed in the Human Genome Mapping Project, the
SNP Consortium Project, and indeed, the sequence itself
have provided cytogeneticists with a new suite of molec-
ular tools with which to analyze chromosomeerican Journal of Human Genetics 84, 524–533, April 10, 2009 525
rearrangements. The use of ﬂuorescence in situ hybridiza-
tion (FISH) and, in particular, the introduction of genomic
array analysis (‘‘molecular karyotyping’’) using array-CGH
or high-density SNP genotyping has revolutionized the
identiﬁcation of subtle (and hitherto unidentiﬁable) cyto-
genetic imbalances.
Contributing to the DECIPHER database is a Consor-
tium, comprising an international network of academic
departments of clinical genetics now numbering more
than 100 centers and having uploaded more than 2000
cases (current statistics can be found on the DECIPHER
homepage). Each contributing center has a nominated
clinical geneticist (with expertise in dysmorphology) and
a nominated molecular cytogeneticist who are jointly
responsible for data entry for their center. Each center
maintains control of its own patient data (which are pass-
word protected within the center’s own DECIPHER
project) until patient consent is given to allow anonymous
genomic and phenotypic data to become viewable within
Ensembl. Once data are shared, consortium members are
able to gain access to the patient report and contact each
other to discuss patients of mutual interest, thus facili-
tating the delineation of new microdeletion and microdu-
plication syndromes. With patient consent, positional
genomic information together with a brief description of
the associated phenotype becomes viewable without pass-
word protection via the DECIPHER track in Ensembl. This
is of beneﬁt not only to clinicians advising patients with
similar ﬁndings but also to researchers working on the
speciﬁc disorders (e.g., congenital heart disease or cleft
lip) seen in that patient or working on the role of genes
contained within the aberration.
Key Features of DECIPHER
(1) DECIPHER integrates seamlessly with the Ensembl
genome browser and interrogates the current version of
the human genome assembly displayed in the Ensembl
genome browser. Because DECIPHER is a dynamic system,
each time it is interrogated the most recent data with re-
gard to gene content are returned into the patient report.
Ensembl itself builds all its annotated genes and associated
features onto the most recent version of the human
genome assembly created by the NCBI (current assembly
NCBI-36). The annotation of genes and their features are
continually being reviewed, reﬁned, and updated, culmi-
nating bimonthly in a new version of the annotation
released onto the Ensembl website. New features and types
of data are continually and routinely added via the distrib-
uted annotation system (DAS16), which allows a set of data
to be dropped into place and viewed across the genome as
a new feature (e.g., copy-number variation (CNV) data).
This approach makes the whole process conﬁgurable and
allows rapid updates to data to be made available.
(2) DECIPHER links to other genetic and medical data-
bases, including HUGO Gene Nomenclature Committee
(HGNC), On-line Mendelian Inheritance in Man
(OMIM), PubMed, GeneReviews, Ensembl genes, Swiss-526 The American Journal of Human Genetics 84, 524–533, April 10Prot, and a frequently updated list of emerging bioinfor-
matics databases. DECIPHER not only displays detected
aberrations in relation to the genome sequence but has
also been programmed to allow the clinician or researcher
to rapidly obtain clinically relevant information (publica-
tions) about the genes located in these regions.
(3) DECIPHER is designed to work with any number of
technologies where position data can be mapped onto
the reference sequence. For DECIPHER to interact directly
with the Ensembl genome browser, positional data
regarding the probes used for analysis must ﬁrst bemapped
onto the reference sequence. DECIPHER can be conﬁgured
to utilize any molecular method (e.g., FISH, MAPH, MLPA,
PCR, array-CGH, or SNP-genotyping) where the probes or
SNPs are positioned on the reference sequence or simply
base-pair position (sequence) itself. Any structural rear-
rangement deﬁned in this way, including copy-number
changes, translocations, and inversions, can be catalogued
within DECIPHER.
(4) DECIPHER uses a restricted ontology of phenotype
terms and speciically the well-known hierarchy of pheno-
type terms developed for the The Baraitser-Winter Neuro-
genetics Database. In this way, clinicians in different
centers use a common set of terms, which facilitates
consistent phenotype description and enables efﬁcient
data sharing and database searching.
(5) DECIPHER facilitates the characterization of copy-
number changes. A major problem in the identiﬁcation
of potentially pathogenic changes is the large number of
normal variants that are identiﬁed, particularly as array
resolution increases. DECIPHER includes a feature graph
tool that displays patient copy-number changes together
with data from the DGV as well as variants identiﬁed in
a selection of the major studies of copy-number variation
in normal individuals. Together with the analysis of
parental samples (see analysis of trios, number 8 below),
each copy-number change in the patient can then be clas-
siﬁed as de novo,CNV (normal variant), or familial variant.
Only de novo changes and familial variants are then dis-
played, with consent, in Ensembl.
(6) DECIPHER provides detailed gene lists for rearrange-
ments. The gene lists and gene displays generated by
DECIPHER are ﬁltered via HGNC to eliminate redundancy
caused by synonyms and to ensure that DECIPHER is using
currently approved gene names. Genes included in the
OMIM Morbid database, i.e., those of known importance
in human disease, are denoted with the sufﬁx M so that
the clinician is immediately alerted to the need to explore
their potential clinical signiﬁcance. Similarly, imprinted
genes listed at the website GeneImprint are denoted by
the sufﬁx I because, in this instance, an inherited deletion
or duplication, although present in a normal parent, can
be potentially pathogenic.
(7) DECIPHER provides a comprehensive search facility.
All of the consented data held within the DECIPHER data-
base are searchable. Features that can be queried include
chromosomal band, genomic position, chromosomes,, 2009
Figure 2. Searching the Genome by Phenotype
Using the phenotype search term ‘‘cleft palate’’ generates an ideogram (below) and list of all the consenting patients that DECIPHER
knows to have cleft palate and displays their genomic aberrations. Two clusters, one on 1q and the other on 5q, are seen together.and phenotypes or a combination of these. DECIPHER
members can also use this search function to interrogate
nonconsented data within their own project group.
(Figure 2).
(8) DECIPHER includes novel software to assist in the
analysis of trios (DNA samples from a patient and both
parents). DECIPHER collects information from array anal-
ysis of both parents and displays this in relation to copy-
number changes found in the patient. This enables the
user to identify whether a genomic aberration identiﬁed
in a patient is of parental origin or has occurred as a de
novo event.
(9) DECIPHER provides advanced text-mining tools for
gene prioritization and for genotype-phenotype correla-
tion. Identifying which gene or genes in a deleted or dupli-
cated region may be responsible for features of the pheno-
type involves considerable literature and database
searching. DECIPHER includes advanced text-mining tools
that order genes in the region according to their likelihood
of being associated in the literature with a phenotypic
feature or group of features.17,18 In addition, because
DECIPHER is directly linked to Ensembl, clinicians and
researchers can identify and query genes that are located
in affected regions of the genome by accessing gene-
speciﬁc databases.
(10) DECIPHER generates both detailed clinical reports
and summary family reports. Once all the phenotype
and genotype data of a patient have been entered into
DECIPHER, two types of printable reports are directly avail-
able from thewebsite. The ﬁrst report comprises a summaryThe Amof the full clinical phenotypic description and an overview
of genes affected by the aberration. This report can be used
as a clinical report and includes the karyotype and ideo-
gram of the affected chromosome(s) and any uploaded
patient images. Alternatively, a simpliﬁed version of the
full clinical report can be printed out for counseling
patients and families.
(11) In order to protect patient privacy, data in
DECIPHER are served over an encrypted SSL (secure socket
layer) connection, similar to a security level employed by
banks and ﬁnancial institutions. Clinical photographs are
an optional element of DECIPHER. When consent is given
for these to be held in DECIPHER, they are password pro-
tected so that they are only accessible to logged-in
members of the consortium. Photographs are digitally
watermarked for additional security. Only cases with docu-
mented full informed consent are visible within the
Ensembl genome browser. Nonconsented data are view-
able only by the submitting center. Public access to con-
sented data is restricted to a basic report identifying
copy-number changes and the phenotype but not the
identity of the submitting center. Requests for further
patient information are made to the DECIPHER adminis-
tration, who pass on the request to the submitting center.
(12) DECIPHER maintains a series of syndrome reports.
The syndromes pages within DECIPHER provide a single,
curated resource of information and web links. As shown
in Figure 3, for each syndrome entity DECIPHER provides
the following: a brief clinical synopsis; information
regarding the size and origin of a deletion or duplication;erican Journal of Human Genetics 84, 524–533, April 10, 2009 527
Figure 3. DECIPHER Syndrome Report for 8p23.1 Deletion Syndrome
Detailed information about known syndromes is maintained by expert advisors within DECIPHER. The copy-number change is displayed on
a ideogram (1), in a genome browser showing normal copy-number variants (2), and with links to OMIN (3) and Ensembl (4).an ideogram of the location of the deletion or duplication
on the relevant chromosome; a list of the genes contained
within the aberrant interval; a direct clickable link to
a visualization of the deletion or duplication in Ensembl;
an up-to-date publication reference list and; a link to
relevant support groups and further information (e.g.,
GeneReviews). DECIPHER Syndromes is supported by a528 The American Journal of Human Genetics 84, 524–533, April 10panel of expert advisors (see Acknowledgments), each
responsible for reviewing and updating the entry for
a speciﬁc syndrome on an annual basis.
Case Studies
Cases are entered into DECIPHER from standard web
browsers, and the data are mapped directly to the latest, 2009
Figure 4. Patient Images
(A) Case 1.
(B) Case 2.
(C) Case 3.human genome assembly via the Ensembl genome
browser. For consenting patients, the aberrant region is
displayed within Ensembl with phenotype information
and any other similar cases within the database, as well
as with other genomic features such as gene content,
segmental duplication, and regions of normal copy-
number variation.
Case Study 1 (DECIPHER 00000797)—Importance of Knowing
the Gene Content
A 28-year-old woman presented to the genetics clinic for
diagnosis. She had mild to moderate learning difﬁculties
and dysmorphic facial features (See Figure 4A). After an
uneventful pregnancy, she was born with bilateral talipes,
which required surgery in infancy. As a young child, she
had been reviewed by pediatricians and geneticists and
had been given a diagnosis of ‘‘peroneal muscular
atrophy.’’
At the clinic she reported experiencing fatigue and lassi-
tude. She appeared anaemic, but there was no history of
menorrhagia, blood loss, or dietary deﬁciency. Investiga-
tions revealed a severe iron-deﬁciency anaemia, Hb 7.1g/dl,
and ferritin<1, and chromosomeanalysis revealed avisible
deletionof 5q21-q22. FISHanalysis reﬁned thebreakpoints,
and the deletionwas then uploaded intoDECIPHER. Genes
located within the deleted region included the APC gene
(MIM 611731). Germline mutations of the APC gene have
been found to be responsible for Familial adenomatous pol-
yposis (FAP [MIM 175100])19,20, a cancer-predisposition
syndrome inwhichhundreds to thousands of precancerous
colonic polyps develop during adolescence. Most muta-
tions in the APC gene are protein truncating and are spread
throughout the coding region of the gene. However, exonic
deletions and whole-gene deletions are also described.20,21
In view of the high risk of colorectal malignancy in adults
with FAP, young people with a diagnosis of FAP are usually
enrolled in a colorectal surveillance program from the ages
of 10–12years andundergoprophylactic colectomy in early
adult life.22The AmAs a result of these ﬁndings, the patient was referred
urgently to a colorectal surgeon for further investigation
and management. Colonoscopy revealed relative sparing
of the rectum, but numerous adenomas were seen
throughout the colon, and there was a large sessile lesion
at the splenic ﬂexure. Furthermore, upper GI endoscopy
demonstrated some gastric fundal and duodenal polyps.
These ﬁndings conﬁrmed the diagnosis of FAP, which
had been predicted from the molecular cytogenetic results.
On account of her high risk of colorectal malignancy, the
patient was admitted for a colectomy with ileorectal anas-
tamosis, and periodic surveillance of the upper GI tract and
rectum was instituted. Sadly, despite this intervention, she
died 18 months later from metastatic carcinoma.
Case Study 2 (DECIPHER 00000128)—A Rare Microdeletion
Syndrome
An 8-year-old boy with complex cyanotic congenital heart
disease, including an atrioventricular septal defect, reﬂux
nephropathy, behavioural problems (impulsivity and
hyperkinetic conduct disorder), andmild learning disability
was seen in thegenetics clinic (see Figure4B).Hisﬁrst cardiac
surgerywas undertaken at the age of 4months, andhehad a
stormypost-operative course, duringwhichhe spent several
weeks in intensive care. He was reviewed by a number of
pediatricians and a pediatric psychiatrist, and it was uncer-
tain to what extent his perioperative complications were
the cause of his learning and behavior problems.
An array-CGH study revealed a small deletion of approx-
imately 4 Mb in size on chromosome 8p23.1.2 From
DECIPHER it was immediately apparent that this deletion
is a rare syndrome, the ‘‘8p23.1 deletion syndrome,’’ which
includes the gene GATA4 (MIM 600576), which encodes
a transcription factor involved in heart formation.23 The
8p23.1 deletion syndrome is characterized by ‘‘develop-
mental delay and a characteristic behavior proﬁle with
hyperactivity and impulsiveness,’’ which explains many
aspects of this child’s phenotype, including his behavioral
and developmental problems.erican Journal of Human Genetics 84, 524–533, April 10, 2009 529
Case Study 3 (DECIPHER 00000126)—Importance of Collabo-
ration to Further Clinical and Scientific Understanding
This case has been previously reported.24 A 4-year-old girl
with developmental delay and poor eye contact was seen
in the genetics clinic for diagnosis (Figure 4C). She was
hypotonic in infancy, and the ﬁrst year of her life was char-
acterized by a lack of social interaction: she did not develop
eye contact or a social smile. She had a normal G-banded
karyotype but harbored a de novo submicroscopic deletion
of approximately 1.1 Mb deﬁned by clones RP11-203M5
(19.853 Mb to 20.059 Mb) and RP11-524O1 (20.736 Mb
to 20.932 Mb) mapping to chromosome 14q11.2. The
case was entered into DECIPHER, and initially no over-
lapping patients were seen. The family was counseled
that the de novo deletion did not appear to overlap any
known copy-number variable regions and was likely to
be the cause of her neurobehavioural problems. However,
because this deletion had not been reported previously,
we could not be certain whether or to what extent it ex-
plained her phenotype.
A year later, two other cases with submicroscopic dele-
tions of 14q11 (DECIPHER 00000976 and 00000977)
were added by colleagues in Vancouver. Evaluation of the
three cases together by Zahir et al24 revealed that all shared
a characteristic pattern of learning disability and a similar
facial appearance (widely spaced eyes, prominent epi-
canthic folds, a very short nose with ﬂat nasal bridge,
long philtrum, prominent Cupid’s bow of the upper lip,
full lower lip, and similar anomalies of the auricles).
Comparison of the three cases revealed a minimal critical
region of 35 kb on chromosome 14q11.2, containing
only two HGNC genes: SUPT16H (MIM 605012) and
CHD8 (MIM 610528), which are both plausible candidates
for genes involved in neurodevelopment.
Genomic microarray analysis brings the opportunity for
much higher diagnostic yield than conventional chromo-
some analysis for patients with developmental delay,
learning disability, dysmorphic features and/or congenital
anomalies. However, this high-resolution information also
brings challenges for the clinical team in the interpretation
of unfamiliar ﬁndings.
DECIPHER in the Clinical Evaluation of Unfamiliar
Aberrations
(1) DECIPHER facilitates the identiﬁcation of whether a re-
arrangement has been seen before in the normal popula-
tion by displaying copy-number-variation tracks from
external studies and databases for each rearrangement
identiﬁed in the patient.
(2) DECIPHER identiﬁes when a ﬁnding overlies a known
syndrome. Whereas clinicians are familiar with the small
number of well-recognized microdeletion disorders that
predate genomic microarray analysis, the rapid prolifera-
tion of new syndromes over the past few years (e.g.,
17q21.325–27 [MIM 610443], 15q2428, TAR syndrome
susceptiblity locus29 [MIM 274000], 14q11.224, and530 The American Journal of Human Genetics 84, 524–533, April 101q2130,31 [MIM 612474]) provides a challenge to clinicians
in staying abreast of new ﬁndings.
(3) DECIPHER displays whether an aberration has been
seen before by another member of the DECIPHER consor-
tium and if so how the phenotypes of the patients
compare.
(4) DECIPHER reports the gene content of the aberra-
tion. For submicroscopic imbalances, the size of the dele-
tion or duplication is a poor guide to its gene content
because the density of genes in the human genome is
very uneven. Some regions are particularly gene rich,
whereas other regions are virtual gene deserts. Gene
content plays an important role in assessment of the
possible pathogenicity of a novel aberration.
(5) DECIPHER shows genes of known clinical impor-
tance within the aberration and provides direct links to
supporting literature to allow the clinician to evaluate
the extent to which these genes may explain the pheno-
type seen in the patient. As illustrated in case 1 (above),
this enables clinicians to be alerted to any genes of poten-
tial clinical importance, e.g., a tumor suppressor gene that,
when deleted, may have important implications for
patient management.
Currently, our understanding of the clinical conse-
quences of changes in copy number is incomplete. When
evaluating a novel copy-number change, one must bear
in mind a large number of different potential mechanisms
of inheritance before dismissing a change as not linked to
the phenotype. These include imprinting; unmasking of
a recessive mutation on the other allele; deletion, duplica-
tion, or rearrangement of regulatory elements; complex
inheritance in which the phenotype results from the inter-
play of more than one genomic alteration and/or SNP; the
possibility that regions that are recognized copy-number
variants in the normal population may have a pathogenic
effect on a speciﬁc genetic background; and the possibility
that there may be thresholding effects at some loci where,
for example, duplication may be better tolerated than trip-
lication or further ampliﬁcation. These factors, together
with awareness that the human genome map continues
to evolve toward a more complete reference sequence
with consequent repositioning of genes and other
elements, need to be considered32,33 because they neces-
sarily imply a degree of caution in interpreting and using
data in DECIPHER.
Although DECIPHER is to our knowledge the only web-
accessible database of microscopic imbalance containing
consented cases with open access and automated instant
display in a public genome browser, similar data from
other patients are accessible elsewhere. Of note is the data-
base ECARUCA, which catalogues large cytogenetic imbal-
ances as well as data from microarray analyses, accessible
to registered members. The combination of all data sources
into a single location would be an ideal, but in practice this
is difﬁcult to achieve due to incompatibilities between
datasets. However, display of data from different databases
within a genome browser where other diverse genomic, 2009
information as well as common disease associations can
also be visualized provides a practical and efﬁcient solution
to this problem.
DECIPHER and the Importance of Rare Dominant
Disease Phenotypes
Many genes in the human genome are still without known
function in human development and disease. For other
genes, the function may be inferred from cross-species
comparison, and for dominantly inherited disorders
(where the phenotype does not abolish reproductive
ﬁtness), genes can be mapped by linkage analysis. Simi-
larly, homozygosity mapping can reﬁne the position of
genes responsible for recessively inherited disorders in
consanguineous families. However, mapping genes for
severe de novo dominant disorders that are reproductively
lethal typically relies upon identifying chromosomal aber-
rations to obtain positional information about gene loca-
tion. The importance of genomic rearrangement as a cause
of sporadic traits has only recently been recognized.34
Indeed, the de novo rate for genomic rearrangement may
be orders of magnitude greater than for point mutations.
Chromosome rearrangements have historically been
important in identifying disease genes by a variety of
approaches: (1) the coincidence of a sporadic occurrence
of the disorder with an apparently balanced de novo auto-
somal reciprocal translocation, e.g., the identiﬁcation of
SATB2 (MIM 608148) as a cleft-palate gene35 and SOX2
(MIM 184429) as an anophthalmia gene36, (2) the segrega-
tion of a phenotype with a translocation, e.g., the identiﬁ-
cation of EOMES (MIM 604615) as a cause of severe neuro-
logical malformation (microcephaly with polymicrogyria
and agenesis of the corpus callosum)37, and (3) the ﬁne
mapping of visible deletions, e.g., the identiﬁcation of
the TSC2 gene38 (MIM 191092). Because high-resolution
genomic microarray analysis has the potential to identify
very small aberrations that may contain only a few genes,
it offers an enhanced opportunity for the discovery of gene
function, as was the case for the identiﬁcation of CHD7
(MIM 608892) as the CHARGE syndrome gene.39
Figure 5. International Collaboration
through DECIPHER
New syndromes defined with the help of
DECIPHER: 17q21.327 in 2006, 14q11.224
in 2007, and 19q13.1144 in 2009.
DECIPHER is designed speciﬁcally
to bring together genomic and pheno-
typic data about submicroscopic chro-
mosome aberrations and other rear-
rangements and display them openly
in the Ensembl genome browser. In
this way, DECIPHER enables clinical
scientistsworldwide not only tomain-
tain records of phenotype and chromosome rearrangement
for their patients but also, with informed consent, to share
this information with the wider research community. By
sharing cases worldwide, critical numbers of rare cases
with phenotypes and structural rearrangements in
common can be identiﬁed. In classical genetics, individuals
with common phenotypes are identiﬁed, and a clinical
syndrome is deliniated, e.g., supravalvular aortic stenosis
and characteristic facies and neurodevelopmental proﬁle
in Williams-Beuren syndrome (WBS [MIM 194050]).40 In
due course, a common genetic basis to the clinical
syndrome is recognized (e.g., a recurrent microdeletion on
7q11.23 was recognized in the case of WBS41). DECIPHER
provides a mechanism for such clinical advances to be
made not only for as-yet-undiscovered recurrent rearrange-
ments but also for the many other patients for whom rear-
rangements are sporadic but overlap a common genomic
region. In this way genomicmicroarray analysis is enabling
the delineation of new syndromes that have less distinctive
clinical features by a process that can be termed ‘‘reverse
dysmorphology.’’ Here, the classical practice of identiﬁca-
tion of the phenotype ﬁrst and analysis of the genotype
second is reversed. In this way, clusters of cases are ﬁrst rec-
ognised by their overlapping copy number changes and
subsequently the phenotypes of the individuals in the
cluster are compared. This new approach permits the recog-
nition of common clinical features that were initially too
subtle or too variable (when seen in patients of different
age, sex, and ethnicity) to enable a new syndrome to be
identiﬁed solely on clinical grounds. This approach may
be particularly valuable for the investigation of disorders
with high locus heterogeneity, e.g., learning disability.
The application of chromosome microarray analysis to
patients with developmental delay, learning disability, dys-
morphic features, and/or congenital anomalies is revolu-
tionizing clinical genetic practice. DECIPHER has the aim
of being a key tool for the clinician in harnessing this
new high-resolution cytogenetic data for the beneﬁt of
patients and their families. DECIPHER has already been
instrumental in deﬁning new syndromes (e.g., 17q21.327,
14q11.224, and 19q13.1142; Figure 5) and will becomeThe American Journal of Human Genetics 84, 524–533, April 10, 2009 531
more powerful not only for clinical diagnosis but also for
genomic research as the number of records in the database
grows.
Web Code
The web code supporting the website is a Perl CGI or
mod_perl web interface with SSL encrypted transport
(HTTPS), Apache web server, Perl Object-Oriented API,
MySQL relational database back-end, and DAS data inte-
gration with Ensembl.
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